Quantcast

Latest Cancer immunoprevention Stories

2014-04-08 10:43:57

The difference between an immune response that kills cancer cells and one that conversely stimulates tumor growth can be as narrow as a "double-edged sword," report researchers at the University of California, San Diego School of Medicine in the April 7, 2014 online issue of the Proceedings of the National Academy of Sciences. "We have found that the intensity difference between an immune response that stimulates cancer and one that kills it may not be very much," said principal...

2014-02-18 04:21:13

New VPs of R&D and Clinical Development add extensive pharmaceutical and biotech immunotherapy product development experience BLUE BELL, Pa., Feb. 18, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has expanded its senior management team with two appointments to help advance the company's growing pipeline of preclinical and clinical DNA vaccines. Inovio has appointed Dr. Laurent Humeau as Vice President of R&D and Dr. Jan Marie-Albert Van...

2013-04-29 11:36:57

A novel drug developed by Gilead Sciences and tested in an animal model at the Texas Biomedical Research Institute in San Antonio suppresses hepatitis B virus infection by stimulating the immune system and inducing loss of infected cells. In a study conducted at Texas Biomed's Southwest National Primate Research Center, researchers found that the immune modulator GS-9620, which targets a receptor on immune cells, reduced both the virus levels and the number of infected liver cells in...

2010-06-02 06:00:00

ROCKVILLE, Md., June 2 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), today announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models. The results of the study, conducted by EntreMed collaborators at the University of Colorado School of Medicine, were published in the June 1, 2010 issue of Clinical Cancer Research (Vol. 16, Issue 11). ENMD-2076, EntreMed's lead oncology...

2009-12-08 09:00:00

NEW ORLEANS, Dec. 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL). The data were presented in an oral presentation(1) at the 51st Annual Meeting of the American Society of Hematology (ASH) and were...

2009-10-08 14:55:36

Older cancer sufferers need treatments tailored to their aging immune systems Elderly cancer patients need a combination of treatments tailor-made to their specific needs to successfully combat the disease. The challenge is to boost their immune response to cancer vaccines, because like the rest of our organs, our immune system ages and gradually becomes less efficient as we get older. Dr. Joseph Lustgarten, from the Mayo Clinic College of Medicine in the US, reviews the effects of aging on...

2009-09-08 14:49:21

Immune responses are capable of killing tumors before they can be directed toward normal body tissue, according to new scientific findings published in Cancer Research, a journal of the American Association for Cancer Research. "There are extremely precise mechanistic methods augmenting the ability of the immune system to distinguish between normal tissues and tumors," said lead researcher Richard G. Vile, Ph.D. "Understanding the multiple checks and safeguards against autoimmunity should...

2009-07-29 10:19:59

Hepatitis B virus (HBV) infection is a dynamic process with variable biochemical, virological and histological profiles at different stages of the infection, depending on host and viral factors. Furthermore, this profile may change at a variable pace over time. The correlation between detection of T-cell response and HBV load in chronic HBV infection remains unknown. In each of the clinical stages of chronic HBV infection, whether the composition of T-cell subpopulations is different and...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related